Is enGene Holdings Inc. (ENGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from October 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.5% / 30% | 33.3% / 30% | 0.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 5.5% / 33% | 33.3% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 14.4% / 33% | 87.5% / 33% | 0.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 5.5% / 33% | 33.3% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 14.4% / 33% | 87.5% / 33% | 0.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -46.1% | |
| Return on Assets (ROA) | -25.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$99M |
| Free Cash Flow | -$101M |
| Total Debt | $32M |
| Debt-to-Equity | 11.9 |
| Current Ratio | 11.8 |
| Total Assets | $221M |
Price & Trading
| Last Close | $6.96 |
| 50-Day MA | $9.05 |
| 200-Day MA | $6.89 |
| Avg Volume | 446K |
| Beta | -0.3 |
|
52-Week Range
$2.65
| |
About enGene Holdings Inc. (ENGN)
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is enGene Holdings Inc. (ENGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), enGene Holdings Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is enGene Holdings Inc.'s debt ratio?
enGene Holdings Inc.'s debt ratio is 5.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 14.4%.
What are enGene Holdings Inc.'s key financial metrics?
enGene Holdings Inc. has a market capitalization of $427M. Return on equity stands at -46.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.